The Molecular Taxonomy of Primary Prostate Cancer

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2015 Nov 7

PMID 26544944

Citations 1616

Affiliations

Soon will be listed here.

Abstract

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course. As part of The Cancer Genome Atlas (TCGA), we present a comprehensive molecular analysis of 333 primary prostate carcinomas. Our results revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1). Epigenetic profiles showed substantial heterogeneity, including an IDH1 mutant subset with a methylator phenotype. Androgen receptor (AR) activity varied widely and in a subtype-specific manner, with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts. 25% of the prostate cancers had a presumed actionable lesion in the PI3K or MAPK signaling pathways, and DNA repair genes were inactivated in 19%. Our analysis reveals molecular heterogeneity among primary prostate cancers, as well as potentially actionable molecular defects.

Citing Articles

Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer.

Ding T, He L, Lin G, Xu L, Zhu Y, Wang X Chin J Cancer Res. 2025; 37(1):90-114.

PMID: 40078560 PMC: 11893346. DOI: 10.21147/j.issn.1000-9604.2025.01.07.

Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future.

Siskin M, Economides M, Wise D Cancers (Basel). 2025; 17(5).

PMID: 40075623 PMC: 11898528. DOI: 10.3390/cancers17050774.

Impact of prostate cancer screening in European ancestry un-affected men with germline DNA repair pathogenic variants.

Fasulo V, Chiarelli G, Garofano G, Ripamonti C, Barile M, Bianchi P BJUI Compass. 2025; 6(3).

PMID: 40066468 PMC: 11891281. DOI: 10.1002/bco2.424.

Rare pathogenic structural variants show potential to enhance prostate cancer germline testing for African men.

Gong T, Jiang J, Uthayopas K, Bornman M, Gheybi K, Stricker P Nat Commun. 2025; 16(1):2400.

PMID: 40064858 PMC: 11893795. DOI: 10.1038/s41467-025-57312-9.

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.

Espin R, Medina-Jover F, Siguenza-Andrade J, Farran-Matas S, Mateo F, Figueras A NAR Cancer. 2025; 7(1):zcaf007.

PMID: 40061566 PMC: 11886861. DOI: 10.1093/narcan/zcaf007.

References

Geng C, He B, Xu L, Barbieri C, Eedunuri V, Chew S . Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013; 110(17):6997-7002. PMC: 3637757. DOI: 10.1073/pnas.1304502110. View

Ghiam A, Cairns R, Thoms J, Dal Pra A, Ahmed O, Meng A . IDH mutation status in prostate cancer. Oncogene. 2011; 31(33):3826. DOI: 10.1038/onc.2011.546. View

Cooperberg M, Broering J, Carroll P . Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009; 101(12):878-87. PMC: 2697208. DOI: 10.1093/jnci/djp122. View

Hovelson D, McDaniel A, Cani A, Johnson B, Rhodes K, Williams P . Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015; 17(4):385-99. PMC: 4415141. DOI: 10.1016/j.neo.2015.03.004. View

Borno S, Fischer A, Kerick M, Falth M, Laible M, Brase J . Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2012; 2(11):1024-35. DOI: 10.1158/2159-8290.CD-12-0041. View

Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H . Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol. 2013; 26(7):975-83. DOI: 10.1038/modpathol.2012.236. View

Kunju L, Carskadon S, Siddiqui J, Tomlins S, Chinnaiyan A, Palanisamy N . Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol. 2014; 22(8):e32-40. PMC: 4159774. DOI: 10.1097/PAI.0000000000000095. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Huether R, Dong L, Chen X, Wu G, Parker M, Wei L . The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun. 2014; 5:3630. PMC: 4119022. DOI: 10.1038/ncomms4630. View

10.

Chandran U, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W . Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007; 7:64. PMC: 1865555. DOI: 10.1186/1471-2407-7-64. View

11.

Rodrigues L, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M . Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 2015; 75(6):1021-34. PMC: 4531265. DOI: 10.1158/0008-5472.CAN-14-1596. View

12.

Boutros P, Fraser M, Harding N, De Borja R, Trudel D, Lalonde E . Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015; 47(7):736-45. DOI: 10.1038/ng.3315. View

13.

Pettersson A, Graff R, Bauer S, Pitt M, Lis R, Stack E . The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012; 21(9):1497-509. PMC: 3671609. DOI: 10.1158/1055-9965.EPI-12-0042. View

14.

Kattan M, Eastham J, Stapleton A, Wheeler T, Scardino P . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90(10):766-71. DOI: 10.1093/jnci/90.10.766. View

15.

Karanika S, Karantanos T, Li L, Corn P, Thompson T . DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene. 2014; 34(22):2815-22. PMC: 4333141. DOI: 10.1038/onc.2014.238. View

16.

Carter S, Cibulskis K, Helman E, McKenna A, Shen H, Zack T . Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012; 30(5):413-21. PMC: 4383288. DOI: 10.1038/nbt.2203. View

17.

Chang M, Asthana S, Gao S, Lee B, Chapman J, Kandoth C . Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2015; 34(2):155-63. PMC: 4744099. DOI: 10.1038/nbt.3391. View

18.

Sboner A, Habegger L, Pflueger D, Terry S, Chen D, Rozowsky J . FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol. 2010; 11(10):R104. PMC: 3218660. DOI: 10.1186/gb-2010-11-10-r104. View

19.

Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin P . Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 2010; 21(1):56-67. PMC: 3012926. DOI: 10.1101/gr.110684.110. View

20.

Geng C, Rajapakshe K, Shah S, Shou J, Eedunuri V, Foley C . Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014; 74(19):5631-43. PMC: 4209379. DOI: 10.1158/0008-5472.CAN-14-0476. View